MedTrace Logo

A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease

NCT04885647 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-12-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the effectiveness and safety of YPEG rhEPO, a recombinant human erythropoietin pegylated by Y shape polyethylene glycol, in patients with anemia due to Chronic Kidney Disease (CKD), assessed by hemoglobin maintenance, adverse events and health-related quality of life.

Conditions

  • Renal Anemia of Chronic Kidney Disease

Interventions

DRUG

YPEG-rhEPO

YPEG-rhEPO，low dose，were subcutaneous injected once every two weeks for 13 weeks.

DRUG

YPEG-rhEPO

YPEG-rhEPO，low dose，were subcutaneous injected once every four weeks for 13 weeks.

DRUG

YPEG-rhEPO

YPEG-rhEPO, high dose，were subcutaneous injected once every two weeks for 13 weeks.

DRUG

YPEG-rhEPO

YPEG-rhEPO，high dose，were subcutaneous injected once every four weeks for 13 weeks.

Sponsors & Collaborators

  • First Affiliated Hospital of Zhejiang University

    collaborator OTHER

  • Xiamen Amoytop Biotech Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-12
Primary Completion
2022-01-05
Completion
2022-01-05

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04885647 on ClinicalTrials.gov